FDA PMA FDA Class 3 Approved 🇺🇸 United States

Drug Coated Prostatic Dilation Catheter For Benign Prostatic Hyperplasia

PMA: P220029 · Supplement: S003 · Decision Dec 15, 2025
Classifications
1
FEI Numbers
0
Registration Numbers
0

Basic Information

Device Name
Drug Coated Prostatic Dilation Catheter For Benign Prostatic Hyperplasia
Trade Name
Optilume™ BPH Catheter System
PMA Number
P220029
Supplement Number
S003
Device Class
FDA Class 3
Product Code
QXB
Generic Name
Drug coated prostatic dilation catheter for benign prostatic hyperplasia
Medical Specialty
Unknown
Advisory Committee
Gastroenterology, Urology
Decision
Approved
Decision Code
APPR
Decision Date
December 15, 2025
Date Received
November 17, 2025
Supplement Type
Normal 180 Day Track No User Fee
Supplement Reason
Postapproval Study Protocol
Expedited Review
N

Advisory Committee Statement

Approval of the revised protocol for the post-approval study (PAS)

Classifications

This FDA Pre-Market Approval entry is associated with 1 FDA classification via its product code.

Product Code Device Name
QXB Drug Coated Prostatic Dilation Catheter For Benign Prostatic Hyperplasia